cute ischemic stroke
Conditions
Interventions
Experimental group:Thrombolytic Therapy
All enrolled patients received standard intravenous reteplase thrombolysis (two 18-mg intravenous boluses administered 30 minutes apart).
Intervention: Tirofiba
Loading dose: 0.4 µg/kg/min intravenously for 30 minutes
Maintenance dose: 0.1 µg/kg/min intravenously for up to 47.5 hours
Oral antiplatelet therapy: Aspirin (100 mg daily) and/or clopidogrel (75 mg
Sponsors
Pingshan District People's Hospital of Shenzhen
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged between 18 and 80 years. 2. Clinically diagnosed with acute ischemic stroke (AIS), with baseline NIHSS score ranging from 4 to 15 points. 3. Symptom onset within = 4 points); (3) Fluctuation of neurological function (NIHSS variability >= 2 points). 7. Written informed consent obtained from the patient or legal authorized representative.
Exclusion criteria
Exclusion criteria: 1. Presence of contraindications to intravenous thrombolysis. 2. Scheduled to receive endovascular therapy. 3. Previous history of intracranial hemorrhage, intracranial neoplasm, arteriovenous malformation or intracranial aneurysm. 4. Major trauma, surgery or active bleeding within the preceding 3 months. 5. Confirmed hypersensitivity to tirofiban or reteplase. 6. Ongoing treatment with oral anticoagulants or intravenous heparin. 7. Platelet count 1.5, or prolonged APTT. 8. Systolic blood pressure>185 mmHg or diastolic blood pressure > 110 mmHg refractory to antihypertensive management. 9. Blood glucose 22.2 mmol/L. 10. Severe hepatic or renal dysfunction: ALT/AST > 3 times the upper limit of normal (ULN), serum creatinine > 2.0 mg/dL. 11. Pregnant or breastfeeding women. 12. Life expectancy less than 90 days. 13. Any other conditions deemed ineligible for enrollment by the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of symptomatic intracranial hemorrhage (sICH) within 48 hours, defined according to the NINDS criteria.; | — |
Secondary
| Measure | Time frame |
|---|---|
| Favorable functional outcome at day 90, defined as modified Rankin Scale (mRS) score of 0–1;Functional independence at day 90, defined as modified Rankin Scale (mRS) score of 0–2;Distribution of modified Rankin Scale (mRS) scores (analyzed with ordinal statistical methods);Early neurological improvement (defined as a >= 4-point reduction in NIHSS score at 24 hours after thrombolysis);Recurrence of ischemic stroke within 90 days;0-day quality of life assessment using the EQ-5D-5L questionnaire;Activities of daily living at day 90 (Barthel Index >= 95 points); | — |
Countries
Shenzhen
Contacts
Public ContactKun Xiao
Pingshan District People's Hospital of Shenzhen
Outcome results
None listed